Deregulation of MiRNAs in Malignant Pleural Mesothelioma is Associated with Prognosis and Suggests an Alteration of Cell Metabolism

Overview

Journal Sci Rep

Specialty Science

Date 2017 Jun 11

PMID 28600498

Citations 31

Authors

Chiara de Santi

Ombretta Melaiu

Alessandra Bonotti

Luciano Cascione

Gianpiero Di Leva

Rudy Foddis

Alfonso Cristaudo

Marco Lucchi

Marco Mora

Anna Truini

Andrea Tironi

Bruno Murer

Renzo Boldorini

Monica Cipollini

Federica Gemignani

Pierluigi Gasparini

Luciano Mutti

Stefano Landi

Affiliations

Soon will be listed here.

Abstract

Malignant pleural mesothelioma (MPM) is an aggressive human cancer and miRNAs can play a key role for this disease. In order to broaden the knowledge in this field, the miRNA expression was investigated in a large series of MPM to discover new pathways helpful in diagnosis, prognosis and therapy. We employed nanoString nCounter system for miRNA profiling on 105 MPM samples and 10 healthy pleura. The analysis was followed by the validation of the most significantly deregulated miRNAs by RT-qPCR in an independent sample set. We identified 63 miRNAs deregulated in a statistically significant way. MiR-185, miR-197, and miR-299 were confirmed differentially expressed, after validation study. In addition, the results of the microarray analysis corroborated previous findings concerning miR-15b-5p, miR-126-3p, and miR-145-5p. Kaplan-Meier curves were used to explore the association between miRNA expression and overall survival (OS) and identified a 2-miRNA prognostic signature (Let-7c-5p and miR-151a-5p) related to hypoxia and energy metabolism respectively. In silico analyses with DIANA-microT-CDS highlighted 5 putative targets in common between two miRNAs. With the present work we showed that the pattern of miRNAs expression is highly deregulated in MPM and that a 2-miRNA signature can be a new useful tool for prognosis in MPM.

Citing Articles

Pleural mesothelioma (PMe): The evolving molecular knowledge of a rare and aggressive cancer.

Rigon M, Mutti L, Campanella M Mol Oncol. 2024; 18(4):797-814.

PMID: 38459714 PMC: 10994233. DOI: 10.1002/1878-0261.13591.

ATG5 as biomarker for early detection of malignant mesothelioma.

Tomasetti M, Monaco F, Strogovets O, Volpini L, Valentino M, Amati M BMC Res Notes. 2023; 16(1):61.

PMID: 37095543 PMC: 10127310. DOI: 10.1186/s13104-023-06330-1.

The Genes-Stemness-Secretome Interplay in Malignant Pleural Mesothelioma: Molecular Dynamics and Clinical Hints.

Stella G, Marchio C, Bari E, Ferrarotti I, Bertuccio F, Di Gennaro A Int J Mol Sci. 2023; 24(4).

PMID: 36834912 PMC: 9963101. DOI: 10.3390/ijms24043496.

Define the Two Molecular Subtypes of Epithelioid Malignant Pleural Mesothelioma.

Saddozai U, Wang F, Khattak S, Akbar M, Badar M, Khan N Cells. 2022; 11(18).

PMID: 36139498 PMC: 9497219. DOI: 10.3390/cells11182924.

Novel Insights Into Mesothelioma Therapy: Emerging Avenues and Future Prospects.

Kuryk L, Rodella G, Staniszewska M, Pancer K, Wieczorek M, Salmaso S Front Oncol. 2022; 12:916839.

PMID: 35785199 PMC: 9247278. DOI: 10.3389/fonc.2022.916839.

References

Li S, Ma Y, Hou X, Liu Y, Li K, Xu S . MiR-185 acts as a tumor suppressor by targeting AKT1 in non-small cell lung cancer cells. Int J Clin Exp Pathol. 2015; 8(9):11854-62. PMC: 4637756. View

Rogers S, Girolami M, Kolch W, Waters K, Liu T, Thrall B . Investigating the correspondence between transcriptomic and proteomic expression profiles using coupled cluster models. Bioinformatics. 2008; 24(24):2894-900. PMC: 4141638. DOI: 10.1093/bioinformatics/btn553. View

Wang C, Yuan P, Li Y . MiR-126 regulated breast cancer cell invasion by targeting ADAM9. Int J Clin Exp Pathol. 2015; 8(6):6547-53. PMC: 4525868. View

Crispi S, Calogero R, Santini M, Mellone P, Vincenzi B, Citro G . Global gene expression profiling of human pleural mesotheliomas: identification of matrix metalloproteinase 14 (MMP-14) as potential tumour target. PLoS One. 2009; 4(9):e7016. PMC: 2737627. DOI: 10.1371/journal.pone.0007016. View

Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D . Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016; 387(10026):1405-1414. DOI: 10.1016/S0140-6736(15)01238-6. View

Wu J, Yin L, Jiang N, Guo W, Gu J, Chen M . MiR-145, a microRNA targeting ADAM17, inhibits the invasion and migration of nasopharyngeal carcinoma cells. Exp Cell Res. 2015; 338(2):232-8. DOI: 10.1016/j.yexcr.2015.08.006. View

Zhang Y, Liu C, Wang J, Li Q, Ping H, Gao S . MiR-299-5p regulates apoptosis through autophagy in neurons and ameliorates cognitive capacity in APPswe/PS1dE9 mice. Sci Rep. 2016; 6:24566. PMC: 4832239. DOI: 10.1038/srep24566. View

Tang H, Liu P, Yang L, Xie X, Ye F, Wu M . miR-185 suppresses tumor proliferation by directly targeting E2F6 and DNMT1 and indirectly upregulating BRCA1 in triple-negative breast cancer. Mol Cancer Ther. 2014; 13(12):3185-97. DOI: 10.1158/1535-7163.MCT-14-0243. View

Manente A, Valenti D, Pinton G, Jithesh P, Daga A, Rossi L . Estrogen receptor β activation impairs mitochondrial oxidative metabolism and affects malignant mesothelioma cell growth in vitro and in vivo. Oncogenesis. 2013; 2:e72. PMC: 3816222. DOI: 10.1038/oncsis.2013.32. View

10.

Reid G, Pel M, Kirschner M, Cheng Y, Mugridge N, Weiss J . Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma. Ann Oncol. 2013; 24(12):3128-35. DOI: 10.1093/annonc/mdt412. View

11.

Zhou S, Liu L, Li H, Eilers G, Kuang Y, Shi S . Multipoint targeting of the PI3K/mTOR pathway in mesothelioma. Br J Cancer. 2014; 110(10):2479-88. PMC: 4021537. DOI: 10.1038/bjc.2014.220. View

12.

Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A . Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002; 3(7):RESEARCH0034. PMC: 126239. DOI: 10.1186/gb-2002-3-7-research0034. View

13.

Zhou R, Wang R, Qin Y, Ji J, Xu M, Wu W . Mitochondria-related miR-151a-5p reduces cellular ATP production by targeting CYTB in asthenozoospermia. Sci Rep. 2015; 5:17743. PMC: 4667214. DOI: 10.1038/srep17743. View

14.

Qiu F, Xiong J, Deng J, Xiang X . TRIM29 functions as an oncogene in gastric cancer and is regulated by miR-185. Int J Clin Exp Pathol. 2015; 8(5):5053-61. PMC: 4503071. View

15.

Gasparini P, Cascione L, Fassan M, Lovat F, Guler G, Balci S . microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers. Oncotarget. 2014; 5(5):1174-84. PMC: 4012726. DOI: 10.18632/oncotarget.1682. View

16.

Fujita Y, Yagishita S, Hagiwara K, Yoshioka Y, Kosaka N, Takeshita F . The clinical relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 network in chemoresistant non-small-cell lung cancer. Mol Ther. 2015; 23(4):717-27. PMC: 4395779. DOI: 10.1038/mt.2015.10. View

17.

Goudarzi H, Iizasa H, Furuhashi M, Nakazawa S, Nakane R, Liang S . Enhancement of in vitro cell motility and invasiveness of human malignant pleural mesothelioma cells through the HIF-1α-MUC1 pathway. Cancer Lett. 2013; 339(1):82-92. DOI: 10.1016/j.canlet.2013.07.020. View

18.

Santarelli L, Strafella E, Staffolani S, Amati M, Emanuelli M, Sartini D . Association of MiR-126 with soluble mesothelin-related peptides, a marker for malignant mesothelioma. PLoS One. 2011; 6(4):e18232. PMC: 3069972. DOI: 10.1371/journal.pone.0018232. View

19.

Pass H, Goparaju C, Ivanov S, Donington J, Carbone M, Hoshen M . hsa-miR-29c* is linked to the prognosis of malignant pleural mesothelioma. Cancer Res. 2010; 70(5):1916-24. PMC: 2831149. DOI: 10.1158/0008-5472.CAN-09-3993. View

20.

Guled M, Lahti L, Lindholm P, Salmenkivi K, Bagwan I, Nicholson A . CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma -A miRNA microarray analysis. Genes Chromosomes Cancer. 2009; 48(7):615-23. DOI: 10.1002/gcc.20669. View